Business
Australian company unlocks a new era for women's health globally with an innovative delivery system for Female testosterone in women with low libido
Acrux is a successful Australian pharmaceutical company that develops innovative drugs for the global market. It recently announced its new strategy to enter the final, phase III clinical trial, stage of development for a Female Testosterone product. This continues the company's heritage in designing and developing patient-preferred drug delivery systems and it address a large unmet patient need. The unmet need is Hypoactive Sexual Desire Disorder (HSDD) or, in common English low libido or low s
About this update from Acrux Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"Massive unmet need for Hypoactive Sexual Desire Disorder treatments addressed by new Female Testosterone product","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase I and II clinical trials completed. Phase III to be done in co-development with global partners.","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Unique, Australian developed unique Patchless Patch™ delivery technology","length":72,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":286,"olType":false},{"type":"text","content":"MELBOURNE, Australia, April 28, 2026 /PRNewswire/ -- Acrux is a successful Australian pharmaceutical company that develops innovative drugs for the global market. It recently announced its new strategy to enter the final, phase III clinical trial, stage of development for a Female Testosterone product. This continues the company's heritage in designing and developing patient-preferred drug delivery systems and it address a large unmet patient need. The unmet need is Hypoactive Sexual Desire Disorder (HSDD) or, in common English low libido or low sex drive in women.","length":575,"tagName":"p"},{"type":"text","content":"HSDD is common in peri and post-menopausal women who make up 10% of the population. Of these around 10% suffer from HSDD. In July, a US Food and Drug Administration (FDA) advisory panel emphasised the importance of finding treatments for women's health challenges, such as HSDD. Testosterone occurs naturally in both men and women but in lower levels in women. One of the leading global experts in HSDD, Dr Susan R Davis AO, MBBS FRACP PhD FAHMS, of Monash University, commented that:","length":493,"tagName":"p"},{"type":"text","content":""Testosterone is not simply a male hormone but is also an important hormone in women. Low sexual desire is the most prevalent sexual concern amongst women. When sufficient to cause personal distress women are considered as having hypoactive sexual desire dysfunction or HSDD.","length":280,"tagName":"p","attribs":{}},{"type":"text","content":"There is irrefutable evidence that testosterone therapy in doses that result in blood levels within the physiological range for premenopausal women improves sexual desire, arousal, orgasm, and sexual self-image and reduces personal distress in postmenopausal women with...